title: [Leishmaniasis treatment].
authors.affiliation: Urgences Pédiatriques, CHU Nord, Marseille, France. philippe.minodier@ap-hm.fr
authors.forename: P
authors.initials: P
authors.lastname: Minodier
authors.forename: A-L
authors.initials: AL
authors.lastname: Jurquet
authors.forename: G
authors.initials: G
authors.lastname: Noël
authors.forename: M
authors.initials: M
authors.lastname: Uters
authors.forename: R
authors.initials: R
authors.lastname: Laporte
authors.forename: J-M
authors.initials: JM
authors.lastname: Garnier
mesh_terms: D000981:Antiprotozoal Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002648:Child; D003906:Developing Countries; D005602:France; D006801:Humans; D016773:Leishmaniasis, Cutaneous / Q000175:diagnosis / Q000188:drug therapy*; D007897:Leishmaniasis, Mucocutaneous / Q000175:diagnosis / Q000188:drug therapy*; D007898:Leishmaniasis, Visceral / Q000175:diagnosis / Q000188:drug therapy*
chemical_list: D000981:Antiprotozoal Agents